Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine

In this phase 3 trial, Kampmann et al.(1) demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth.

Detalles Bibliográficos
Autores principales: Miller, Ann M., Varga, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313928/
https://www.ncbi.nlm.nih.gov/pubmed/37343524
http://dx.doi.org/10.1016/j.xcrm.2023.101081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313928/
https://www.ncbi.nlm.nih.gov/pubmed/37343524
http://dx.doi.org/10.1016/j.xcrm.2023.101081

Ejemplares similares